Is HIND or HRTX more undervalued in 2026?

CirclFi compares Vyome Holdings, Inc. (HIND) and Heron Therapeutics, Inc. (HRTX) using 13 institutional-grade valuation models. HIND has a Quality of Company score of 5.1/10 while HRTX scores 6.1/10.

Which is a better buy — HIND or HRTX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HIND and HRTX valuations compare?

HIND at $2.34 and HRTX at $0.87 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HIND vs HRTX Valuation Comparison 2026 — Intrinsic Value Analysis

HIND

Pharmaceutical Preparations

Vyome Holdings, Inc.

Quality

5.1

out of 10

Value Trap

LOW

Price

$2.34

Last close

Models

12/13

Active

HRTX

Pharmaceutical Preparations

Heron Therapeutics, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$0.87

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	HIND Fair Value	HIND Upside	HRTX Fair Value	HRTX Upside
Bayesian DCF	Intrinsic	$0.78	-66.7%	$0.26	-70.4%
Earnings Power Value	Intrinsic	$0.88	-55.2%	$0.16	-86.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HIND vs HRTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HIND vs HRTX — Which Stock Is More Undervalued?

HRTX scores higher with a 6.1/10 quality rating vs HIND's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Vyome Holdings, Inc. (HIND) and Heron Therapeutics, Inc. (HRTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HIND currently trades at $2.34 with a QOC of 5.1/10, while HRTX trades at $0.87 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).